ReviewFrontiers in oncology2026
Lobular breast cancer and prognosis: what should we tell patients?
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. It accounts for up to 15% of all breast cancer diagnoses, and there is an increasing population of people living with a diagnosis of 'lobular'. ILC has historically been understudied and is underrepresented in clinical trials. Presenting with pathology features typical of a good prognosis (oestrogen receptor-positive, HER2-negative, grade 2), a diagnosis of ILC can be framed as one with a 'good outcome'. But whether the data support this over time remains to be seen. Methods: We present a comprehensive narrative review to ascertain whether ILC has a better outcome than invasive carcinoma of no special type (IC-NST). Results: A number of the research studies analysed showed that ILC can have a better outcome at 5 years and still have a poorer outcome over time, whilst others showed that IC-NST has a poor outcome early, which is maintained over time. Conclusions: We discuss limitations and confounders and, critically, give voice to the people living with a lobular breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.